Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

MetroRock1000 Sep. 11 at 8:45 PM

$EXEL going up

0 · Reply

Jblack500 Sep. 5 at 3:50 PM

$GILD $BBIO $ABBV $SMMT $EXEL yup gild

0 · Reply

Jblack500 Sep. 3 at 5:44 PM

$GILD $BBIO $ABBV $SMMT $EXEL just bought more gilead...also added some last week near 113...it's making the turn higher in uptrend and currently in max gain buy zone

0 · Reply

Tangle22 Sep. 2 at 7:00 PM

$EXEL down but $IBB up do your what with exel

0 · Reply

theimpatienttrader Aug. 29 at 3:35 PM

$EXEL a reversal will validate the sept 40calls which are trading at a quarter now after a big buy at 1.00 after the last E.R

0 · Reply

SmartOrderRouter Aug. 27 at 4:38 AM

$EXEL building a base, watching for breakout confirmation.

0 · Reply

Jblack500 Aug. 26 at 4:35 PM

$GILD $ABBV $SMMT $EXEL $BBIO Bought more gild 114.40. Took advantage of recent pullback. I see it bouncing off this 114 area. Raised my cost basis to 84 dollars....GL

0 · Reply

ZacksResearch Aug. 26 at 1:45 PM

$EXEL's Cabometyx: Significant Boost in Neuroendocrine Tumors 🚀 FDA approval for label expansion boosts its lead drug's potential Captures 35% of new patient share for oral therapies in this indication Discover what this means for EXEL investors 👉 https://www.zacks.com/stock/news/2742791/can-label-expansion-of-cabometyx-fuel-further-growth-for-exel?cid=sm-stocktwits-2-2742791-body-9492&ADID=SYND_STOCKTWITS_TWEET_2_2742791_BODY_9492

0 · Reply

Jblack500 Aug. 26 at 1:27 PM

$GILD $ABBV $BBIO $EXEL $SMMT Holding these 5 winners for quite a while now. Was in pcyc when it was acquired..pcyc former ceo runs smmt

1 · Reply

ZacksResearch Aug. 26 at 12:45 PM

$EXEL just got a growth catalyst — but how big could it be? FDA approval to expand Cabometyx into neuroendocrine tumors is already seeing encouraging uptake, putting fresh momentum behind the stock. Discover if this expansion can fuel the next leg of growth 👉 https://www.zacks.com/stock/news/2742791/can-label-expansion-of-cabometyx-fuel-further-growth-for-exel?cid=sm-stocktwits-2-2742791-teaser-9490&ADID=SYND_STOCKTWITS_TWEET_2_2742791_TEASER_9490

0 · Reply

Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:06 PM EDT - 4 days ago

Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 10:06 AM EDT - 9 days ago

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

Sep 3, 2025, 7:43 PM EDT - 9 days ago

Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:43 PM EDT - 10 days ago

Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Aug 29, 2025, 5:47 PM EDT - 15 days ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 27, 2025, 4:05 PM EDT - 17 days ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Aug 25, 2025, 6:01 PM EDT - 19 days ago

Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters

Jul 31, 2025, 12:27 PM EDT - 6 weeks ago

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

Jul 29, 2025, 12:32 PM EDT - 6 weeks ago

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Jul 28, 2025, 10:51 PM EDT - 6 weeks ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 4:05 PM EDT - 6 weeks ago

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 5:04 PM EDT - 7 weeks ago

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jul 14, 2025, 4:05 PM EDT - 2 months ago

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 12:58 PM EDT - 2 months ago

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Jun 23, 2025, 10:37 AM EDT - 2 months ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 2 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 3 months ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

May 23, 2025, 6:25 AM EDT - 4 months ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 4 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 4 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 4 months ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 4 months ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 4 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:06 PM EDT - 4 months ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 4:07 PM EDT - 4 months ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 4 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Apr 29, 2025, 4:05 PM EDT - 4 months ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 29, 2025, 2:02 AM EDT - 4 months ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Mar 26, 2025, 9:15 AM EDT - 6 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Mar 25, 2025, 5:15 PM EDT - 6 months ago

Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025

Mar 19, 2025, 7:09 AM EDT - 6 months ago

Exelixis Growth Continues with Big Money Boosts

Feb 25, 2025, 4:05 PM EST - 7 months ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Feb 21, 2025, 1:30 PM EST - 7 months ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Feb 20, 2025, 5:05 PM EST - 7 months ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Feb 15, 2025, 11:10 AM EST - 7 months ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Feb 13, 2025, 4:05 PM EST - 7 months ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

Feb 12, 2025, 9:04 AM EST - 7 months ago

Exelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon Follow

Feb 11, 2025, 8:24 PM EST - 7 months ago

Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 4:05 PM EST - 7 months ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

Jan 28, 2025, 4:05 PM EST - 8 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 25, 2025, 10:00 AM EST - 8 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

Jan 24, 2025, 2:30 PM EST - 8 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Jan 22, 2025, 7:44 AM EST - 8 months ago

Revenues, Treatment Pipeline Driving Exelixis Higher

Jan 12, 2025, 4:00 PM EST - 8 months ago

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

Jan 10, 2025, 5:29 PM EST - 8 months ago

The Best Defensive Stocks To Hedge Against Market Uncertainty

EXC PM PPC RTX

MetroRock1000 Sep. 11 at 8:45 PM

$EXEL going up

0 · Reply

Jblack500 Sep. 5 at 3:50 PM

$GILD $BBIO $ABBV $SMMT $EXEL yup gild

0 · Reply

Jblack500 Sep. 3 at 5:44 PM

$GILD $BBIO $ABBV $SMMT $EXEL just bought more gilead...also added some last week near 113...it's making the turn higher in uptrend and currently in max gain buy zone

0 · Reply

Tangle22 Sep. 2 at 7:00 PM

$EXEL down but $IBB up do your what with exel

0 · Reply

theimpatienttrader Aug. 29 at 3:35 PM

$EXEL a reversal will validate the sept 40calls which are trading at a quarter now after a big buy at 1.00 after the last E.R

0 · Reply

SmartOrderRouter Aug. 27 at 4:38 AM

$EXEL building a base, watching for breakout confirmation.

0 · Reply

Jblack500 Aug. 26 at 4:35 PM

$GILD $ABBV $SMMT $EXEL $BBIO Bought more gild 114.40. Took advantage of recent pullback. I see it bouncing off this 114 area. Raised my cost basis to 84 dollars....GL

0 · Reply

ZacksResearch Aug. 26 at 1:45 PM

0 · Reply

Jblack500 Aug. 26 at 1:27 PM

$GILD $ABBV $BBIO $EXEL $SMMT Holding these 5 winners for quite a while now. Was in pcyc when it was acquired..pcyc former ceo runs smmt

1 · Reply

ZacksResearch Aug. 26 at 12:45 PM

0 · Reply

ZacksResearch Aug. 25 at 1:58 PM

$EXEL vs. $MRK: Which stock should you bet on? 💊 ✅ EXEL gains 16.1% YTD, driven by Cabometyx and strong pipeline updates. 📈 MRK offers a robust, diverse portfolio with Keytruda as a key revenue driver and an attractive 3.71% dividend yield. Discover which stock stands out as a better pick here 👉 https://www.zacks.com/stock/news/2741976/exelixis-vs-merck-which-oncology-stock-is-a-better-pick-as-of-now?cid=sm-stocktwits-2-2741976-body-9274&ADID=SYND_STOCKTWITS_TWEET_2_2741976_BODY_9274

0 · Reply

ZacksResearch Aug. 25 at 12:58 PM

$EXEL vs $MRK — which oncology giant wins now? 🧬 EXEL is fueled by Cabometyx momentum and pipeline progress, while MRK banks on Keytruda dominance plus a diverse portfolio. Full breakdown here 👉 https://www.zacks.com/stock/news/2741976/exelixis-vs-merck-which-oncology-stock-is-a-better-pick-as-of-now?cid=sm-stocktwits-2-2741976-teaser-9272&ADID=SYND_STOCKTWITS_TWEET_2_2741976_TEASER_9272

0 · Reply

theimpatienttrader Aug. 20 at 1:26 PM

$EXEL I'd love to buy some protective puts in this today under 37.50 but this thing is trading on the market makers feeling of the day

0 · Reply

ZacksResearch Aug. 19 at 1:35 PM

$EXEL: Consistent Buyback or Overpriced Play? 🤔 EXEL has been consistently repurchasing shares, with $796.3M bought back, reducing shares outstanding and boosting shareholder value. Yet, its price/sales ratio of 4.07x signals a potentially pricey investment compared to the industry average. 📈 See if EXEL's strategy pays off for investors 👉 https://www.zacks.com/stock/news/2734902/will-exels-share-repurchase-program-boost-value-for-investors?cid=sm-stocktwits-2-2734902-body-8281&ADID=SYND_STOCKTWITS_TWEET_2_2734902_BODY_8281

0 · Reply

ZacksResearch Aug. 19 at 12:35 PM

$EXEL just dropped $796M on buybacks — smart capital move or dead money? The company’s repurchase program is designed to lift EPS and drive shareholder value through 2025. Full breakdown on what this means for investors 👉 https://www.zacks.com/stock/news/2734902/will-exels-share-repurchase-program-boost-value-for-investors?cid=sm-stocktwits-2-2734902-teaser-8280&ADID=SYND_STOCKTWITS_TWEET_2_2734902_TEASER_8280

0 · Reply

Reanimated666 Aug. 15 at 2:11 PM

$BBIO Taking 25 percent gains here Largely outperformed $EXEL and more than recovered any losses i occurred

1 · Reply

OtherOtttawaGuy Aug. 14 at 7:32 PM

$EXEL Expiration Max Pain Max Pain vs Current Price Aug 15, 2025 (1 days) (m) 37.00 -1.31 (-3.42%) Sep 19, 2025 (36 days) (m) 38.00 -0.31 (-0.81%) Oct 17, 2025 (64 days) (m) 30.00 -8.31 (-21.69%) Nov 21, 2025 (99 days) (m) 40.00 1.69 (4.41%) Jan 16, 2026 (155 days) (m) 37.00 -1.31 (-3.42%) Feb 20, 2026 (190 days) (m) 37.00 -1.31 (-3.42%) Jan 15, 2027 (519 days) (m) 25.00 -13.31 (-34.74%)

1 · Reply

theimpatienttrader Aug. 14 at 3:58 PM

$EXEL easy short under 37.50 if you need to hedge with puts

1 · Reply

theimpatienttrader Aug. 14 at 2:30 PM

$EXEL this must be a buyout target not to pump but how do you explain the buying when it has no room to go up or down with support and limited upside price targets and valued at 10B

1 · Reply

ZacksResearch Aug. 14 at 1:30 PM

$EXEL hit a 52-week high on June 23, 2025, but can it sustain the momentum? 📈 Cabometyx's demand is strong, boosted by its new indication for previously treated NET, yet the recent quarterly revenue miss has investors cautious. Meanwhile, positive data on zanzalintinib sparks optimism despite competitive pressures in the RCC space. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2711934/exelixis-gains-156-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2711934-body-7840&ADID=SYND_STOCKTWITS_TWEET_2_2711934_BODY_7840

0 · Reply

ZacksResearch Aug. 14 at 12:30 PM

$EXEL up 15.6% YTD — bullish trend or trap? Cabometyx growth and zanzalintinib trial wins fuel optimism, but a Q2 revenue miss and competitive pressures are keeping sentiment in check. Full bull/bear breakdown here 👉 https://www.zacks.com/stock/news/2711934/exelixis-gains-156-ytd-how-should-you-play-the-stock?cid=sm-stocktwits-2-2711934-teaser-7839&ADID=SYND_STOCKTWITS_TWEET_2_2711934_TEASER_7839

0 · Reply

ZacksResearch Aug. 13 at 1:49 PM

$EXEL in focus: Is zanzalintinib the game-changer they need? 🔄 The STELLAR-303 study showed a significant improvement in overall survival, marking a key win for EXEL's investigational drug. But, with heavy competition in the RCC space for Cabometyx, EXEL faces challenges. Full analysis here 👉 https://www.zacks.com/stock/news/2706875/will-zanzalintinib-ease-out-exels-reliance-on-cabometyx-for-growth?cid=sm-stocktwits-2-2706875-body-7593&ADID=SYND_STOCKTWITS_TWEET_2_2706875_BODY_7593

0 · Reply

Market Cap	10.52B
Revenue (ttm)	2.17B
Net Income (ttm)	521.27M
EPS (ttm)	N/A
PE Ratio	18.30
Forward PE	16.11
Profit Margin	24.04%
Debt to Equity Ratio	0.00

Volume	2,475,700
Avg Vol	3,058,102
Day's Range	N/A - N/A
Shares Out	269.20M
Stochastic %K	96%
Beta	0.32
Analysts	Strong Sell
Price Target	$44.95